Clinical Trial: Clinical value of novel biomarker anti-BNLF2b antibody combined with EBV Rta-IgG and EBV VCA-IgA detection in early diagnosis of nasopharyngeal carcinoma patients (China)

Posted On: 2026-09-08

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical value of novel biomarker anti-BNLF2b antibody combined with EBV Rta-IgG and EBV VCA-IgA detection in early diagnosis of nasopharyngeal carcinoma patients'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131852

Registration Time: 2026/09/07

Type: Observational study

Primary Sponsor: The First People's Hospital of Foshan

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=314212

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Clinical value of novel biomarker anti-BNLF2b antibody combined with EBV Rta-IgG and EBV VCA-IgA detection in early diagnosis of nasopharyngeal carcinoma patients (China)